Journal: Cell Reports Medicine

Article Title: T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges

doi: 10.1016/j.xcrm.2026.102772

Figure Lengend Snippet: Representative BsAb constructs Examples of BsAb architectures under clinical or preclinical evaluation in myeloid malignancies. AMG330 (CD33) is the first BiTE/T-BsAb tested clinically in AML; flotetuzumab (CD123) is the first DART molecule in the clinic. CD16×CD33 BiKEs show preclinical activity, and TriKEs such as GTB-3550 incorporate IL-15 to enhance NK cell function. Additional emerging platforms include BsADCs (e.g., BVX001), CITEs (e.g., PD-1–CD33–CD3), BICEs (e.g., XCR1–CLEC9A–PD-1), and TETRICE molecules (e.g., IL1RL1-targeting constructs). Abbreviations: VH, variable region of the heavy chain; VL, variable region of the light chain; scFv, single-chain fragment variable; BsAb, bispecific antibody; BiTE, bispecific T cell engager; DART, dual-affinity re-targeting protein, BiKE, bispecific killer cell engager; TriKE, trispecific killer cell engager; BsADC, bispecific antibody-drug conjugate; TriTE, trispecific T cell engager; CITE, checkpoint inhibitor T cell engager; BICE, bispecific dendritic-T cell engager; TETRICE, tetraspecific T cell engager.

Article Snippet: Several T-BsAbs against CD33 are under development, with the first developed by Amgen (AMG330).

Techniques: Construct, Activity Assay, Cell Function Assay